Cohort (CHRT)
London Exchange · UK · prices in GBX · close of 21 Oct 2026
Key indicators
| Last close | GBX 1,290.00 |
|---|---|
| 52-week range | 860.05 – 1,509.76 |
| Return, 1 month / 3 months | +9.5% / −0.0% |
| Return, 1 year / 3 years | −1.8% / +184.7% |
| Trend | Uptrend |
| RSI (14) | 62 |
| Volatility (1 year) | 45.9% |
| Worst drawdown (1 year) | -35.0% |
| Average daily value traded | 151.53M GBX |
| Dividend yield | 0.0% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Cohort is a holding company that owns a group of businesses supplying technology and services to defence and security customers. Its subsidiaries work on areas such as electronic warfare, secure communications, training and simulation, and naval systems, serving government and military customers mainly in the United Kingdom and abroad. The company is based in the United Kingdom and operates through its individual trading businesses rather than as a single brand.
Cohort trades under the code CHRT on the London Exchange in UK, with its price quoted in pence sterling (GBX). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Cohort (CHRT) trades on the London Exchange in UK. It last closed at GBX 1,290.00 on 21 October 2026.
Its price-based Market X-Ray is 50 out of 100 (a weak price profile), ranking 2,071 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 1.8% and over the last three months it fell 0.0%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 57 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 5.5% | ||
| From 52-week high | -10.8% | ||
| Momentum | 41 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | 0.0% | ||
| 6-month return | -0.1% | ||
| 12-month return, skipping the last month | -10.3% | ||
| Stability (higher is calmer) | 35 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 45.9% | ||
| Worst drawdown, 1 year (smaller is calmer) | -35.0% | ||
| Liquidity | 91 · Strong | Trades actively. | |
| Average daily value traded | 151.53M GBX | ||
| Zero-volume days | 0.0% | ||
| Income | 26 · Weak | Dividend is small or irregular. | |
| Dividend yield | 0.0% | ||
| Years with dividends | 5 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Income: Dividend is small or irregular.
Returns
| 1 week | +2.4% |
|---|---|
| 1 month | +9.5% |
| 3 months | −0.0% |
| 6 months | −0.1% |
| 1 year | −1.8% |
| 3 years | +184.7% |
| 5 years | +146.2% |
Signals
| 50-day / 200-day average | 1,219.68 / 1,223.04 |
|---|---|
| Golden / death cross (60 days) | Death, 1 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 63.56 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 20 Aug 2026 | GBP 0.1210 |
| 20 Jul 2026 | GBP 0.1210 |
| 8 Jan 2026 | GBP 0.0580 |
| 21 Aug 2025 | GBP 0.1105 |
| 9 Jan 2025 | GBP 0.0525 |
| 22 Aug 2024 | GBP 0.1010 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.